GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Float Percentage Of Total Shares Outstanding

ATHA (Athira Pharma) Float Percentage Of Total Shares Outstanding : 69.85% (As of Mar. 18, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Athira Pharma's float shares is 27.27 Mil. Athira Pharma's total shares outstanding is 39.04 Mil. Athira Pharma's float percentage of total shares outstanding is 69.85%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Athira Pharma's Insider Ownership is 6.02%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Athira Pharma's Institutional Ownership is 46.40%.


Athira Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Athira Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=27.27/39.04
=69.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athira Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Executives
Mark James Litton officer: Chief Operating Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington officer: General Counsel C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Kevin Church officer: Vice President of Discovery 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Rachel Lenington officer: Chief Technology Officer C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Andrew Gengos officer: See Below 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Kelly A Romano director C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Grant Pickering director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Glenna Mileson officer: Chief Financial Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Hans Moebius officer: Chief Medical Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara director 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014